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CHAPTER 1 
1.0 THE DISCOVERY OF HUMAN IMMUNODEFICIENCY VIRUS 
On July 3, 1981, the New York Times published an article detailing the diagnosis of a 
rare form of cancer called Kaposi’s Sarcoma among 41 homosexual men primarily in 
New York City and the San Francisco Bay Area over a period of 30 months [1]. Until 
that time, the nationwide incidence of this disease was one case in every 1.5 million 
people as reported by the Centers for Disease Control (CDC). Two years later, with 
1,350 reported cases, viral DNA from a human T-lymphotrophic retrovirus was isolated 
from the T cells of several patients exhibiting symptoms common to what is now called 
Acquired Immune Deficiency Syndrome (AIDS) [2]. The enveloped virus was named 
Human Immunodeficiency Virus (HIV), and its discovery earned Drs. Françoise Barré-
Sinoussi and Luc Montagnier the Nobel Prize in Physiology or Medicine in 2008. It was 
classified as belonging to genus Lentivirus in the Retroviridae family. The lentiviral 
classification denotes the protracted period of latency which, in the case of HIV, can 
exceed seven-ten years before the emergence of opportunistic infections that are 
collectively referred to as AIDS [3].  
Since 1985, the availability of serologic tests to detect HIV infection has allowed to 
estimate the real size of the epidemic.  
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1.1 AN OVERVIEW OF HIV/AIDS EPIDEMIC 
Today, HIV is a global pandemic. It is estimated that HIV/AIDS has claimed the lives of 
25 million people with an estimated 33.3 million people living with the disease in 2009 
[4]. The majority of people with HIV/AIDS are living in developing countries. In 
particular, the sub-Saharan Africa region, which has adult prevalence of 5%, has 
continued to bear the overwhelming burden of the epidemic. Sub-Saharan Africa has 
about two-thirds of all people living with HIV/AIDS globally [4]. Table 1 below shows 
the summary of estimates of HIV and AIDS at the end of the year 2009. 
 
Table 1: Estimates of HIV and AIDS at the end of year 2009  
 Global number of people  
(in millions) 
Sub-Saharan Africa 
(in millions) 
Living with HIV/AIDS in year 2009 33.3 22.5 
Newly infected with HIV in year 2009 2.6 1.8 
Died due to AIDS in year 2009 1.8 1.3 
Source: (UNAIDS/WHO, 2010). AIDS epidemic update, December 2010  
 
In Italy the surveillance system of new HIV infections was established by a decree of the 
Ministry of Health in 2008 and receives data from the country’s regions and provinces.  
Some regions had already collected data on new diagnoses before the system existed, as 
early as 1985. According to these data, the incidence of HIV infection in Italy peaked at 
the end of the 1980s and followed by a progressive decrease until the end of the 1990s.  
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Afterwards, the number of new infections stabilized. In 2009 it was estimated an 
incidence of new HIV diagnoses of 4.6 per 100,000 population among persons with 
Italian nationality and of 22.5 per 100,000 population among non-nationals (Fig. 1).  
Moreover, in the same year, it was evaluated that almost one third of the persons with 
HIV infection were of foreign nationality (Fig. 2). The median age of newly diagnosed 
cases has increased over time: in 2009, it was of 39 years for males and 36 years for 
females (Fig. 3). Cases attributable to heterosexual contact or contact among men who 
have sex with men (MSM) are steadily increasing, accounting for 79% of all reported 
cases in 2009 (Fig. 4). In 2009, one third of the persons with a new HIV diagnosis were 
diagnosed at an advanced stage of illness, with significant impairment to their immune 
systems (Fig. 5). Regarding to AIDS cases, the surveillance system, that was created in 
1984, recorded that since the beginning of the epidemic in 1982, about 63,000 cases of 
AIDS have been reported and nearly 40,000 of them have died. The number of new 
AIDS cases reported each year has decreased since 1996, mainly because of 
antiretroviral therapies introduced in Italy in the same year [5].  
Although the development of highly active antiretroviral therapy (HAART) in 1996 is 
credited for the precipitous drop in AIDS-related morbidity and mortality in developed 
countries such as the United States and Europe, the costs associated with HAART and 
the lack of robust health care infrastructures has hindered their widespread use in most 
developing countries. It was reported that by the end of 2007, the number of people 
receiving HAART in developing countries had reached the 3 million – roughly 10% of 
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those in need [4]. The combination of economic, logistical, and political barriers to 
treatment is particularly alarming given that nearly 95% of all HIV-infected people live 
in developing regions of the world such as sub-Saharan Africa and Asia. Education and 
sexually transmitted disease control programs have proven to be effective strategies for 
reducing the spread of HIV, but the need to develop an inexpensive vaccine capable of 
preventing or controlling an infection remains one of the most important challenges in 
combating the pandemic. 
 
1.2 MOLECULAR AND BIOLOGIC FEATURES OF HIV 
1.2.0 HIV Structure and Genes 
HIV is a member of the lentivirus family of animal retroviruses. Two closely related 
types of HIV, designated HIV-1 and HIV-2, have been identified. HIV-1 is by far the 
most common cause of AIDS, but HIV-2, which differs in genomic structure and 
antigenicity, causes a similar clinical syndrome.  
HIV consists of two identical strands of RNA packaged within a core of viral proteins 
and surrounded by a phospholipid bilayer envelope derived from the host cell membrane 
but including virally encoded membrane proteins (Fig. 6). Long terminal repeats (LTRs) 
at each end of the genome regulate viral gene expression, viral integration into the host 
genome, and viral replication. The gag sequences encode core structural proteins. The 
env sequences encode the envelope glycoproteins gp120 and gp41, which are required 
for infection of cells. The pol sequences encode reverse trascriptase, integrase, and viral 
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protease enzymes required for viral replication. In addition to these typical retrovirus 
genes, HIV-1 also includes six other regulatory genes, namely, the tat, rev, vif, nef, and 
vpu genes, whose products regulate viral reproduction in various ways [6]. 
 
1.2.1 Viral Life Cycle 
HIV infection of cells begins when the envelope glycoprotein (Env) of a viral particle 
binds to both CD4 and coreceptor that is a member of the chemokine family. The viral 
particles that initiate infection are usually in the blood, semen, or other body fluid of one 
individual and are introduced into another individual by sexual contact, needle stick, or 
transplacental passage. Env is a complex composed of a transmembrane gp41 subunit 
and an external, nonconvalently associated gp120 subunit. The first step of viral life 
cycle is the binding of gp120 subunits to CD4 molecules [7], which induces a 
conformational change that promotes secondary gp120 binding to a chemokine 
coreceptor. Coreceptor binding induces a conformational change in gp41 that exposes a 
hydrophobic region, called the fusion peptide, that inserts into the cell membrane and 
enables the viral membrane to fuse with the target cell membrane. After the virus 
completes its life cycle in the infected cell, free viral particles are released from one 
infected cell and bind to an uninfected cell, thus propagating the infection. In addition, 
gp120 and gp41, which are expressed on the plasma membrane of infected cells before 
virus is released, can mediate cell-fusion with an uninfected cell that expresses CD4 and 
coreceptor, and HIV genomes can then be passed between the fused cells directly. 
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More than seven different chemokine receptor have been shown to serve as coreceptors 
for HIV entry into cells, but those most important are CCR5 and CXCR4 [8]. HIV-1 
isolates can be divided in three broad groups based on coreceptor used. Variants with 
singular use of CCR5 and CXCR4 are termed R5 and X4 viruses, respectively, while 
those capable using both coreceptors are termed R5X4.  
Because CCR5 is expressed on the surface of the macrophages (and some memory T 
cells), HIV strains that use this coreceptor are macrophages-tropic (M-tropic) whereas 
those that use CXCR4, expressed on the surface of the T cells, are T-tropic. HIV strains 
the use both coreceptor are dual-tropic viruses. In many HIV-infected individuals, there 
is a change from the production of virus that uses CCR5, in the early stages of the 
disease, to virus that binds to CXCR4, in the later stages of the disease. The T-tropic 
strains tend to be more virulent, presumably because they infect and deplete T cells 
more than do M-tropic strains.  
Once an HIV virion enters a cell, the enzymes within the nucleoprotein complex become 
active and begin the viral reproductive cycle. The nucleoprotein core of the virus 
becomes disrupted, the RNA genome of HIV is transcribed into a double-stranded DNA 
form by viral reverse transcriptase, and the viral DNA enters the nucleus. The viral 
integrase also enters the nucleus and catalyzes the integration of viral DNA into the host 
cell genome. The integrated HIV DNA is called the provirus. The provirus may remains 
transcriptionally inactive for months or years, with little or no production of new viral 
proteins or virions, and in this ways HIV infection of an individual cell can be latent.   
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Initiation of HIV gene transcription in T cells is linked to activation of the T cells by 
antigen or cytokines [9]. For example, cytokines such us IL2, TNF, and lymphotoxin 
stimulate HIV gene expression in infected T cells, and IL1, IL3, IL6, TNF, lymphotoxin, 
and IFN-γ stimulate HIV gene expression and viral replication in infected monocytes 
and macrophages. This phenomenon is significant to the pathogenesis of AIDS because 
the normal response of a latently infected T cell to a microbe involves the end of the 
latency. The multiple infections that AIDS patients acquire thus stimulate production 
and infection of additional cells. 
 
1.3 PATHOGENESIS OF HIV INFECTION AND AIDS 
HIV disease begin with acute infection and advances to chronic progressive infection of 
peripheral lymphoid tissues. Acute infection is characterized by infection of memory 
CD4+ T cells (which express CCR5) in mucosal lymphoid tissues, and death of many 
infected cells [10].   
The transition from acute phase to a chronic phase of infection is characterized by 
dissemination of the virus (viremia) and the development of host immune response. This 
immune response partially control the infection and viral production, and such control is 
reflected by a drop in viremia to low but detectable levels by approximately 12 weeks 
after the primary exposure.  
In the next chronic phase of the disease, lymph nodes and the spleen are sites of 
continuous HIV replication and cell destruction. During this period of the disease, the 
 8
immune system remains competent and few or no clinical manifestations of the HIV 
infection are present. Therefore, this phase of HIV disease is called the clinical latency 
period. Although the majority of peripheral blood T cells do not harbor the virus, 
destruction of CD4+ T cells within lymphoid tissues progresses during the latent period, 
and the number of circulating blood CD4+ T cells steadily declines [11]. 
 
1.3.0 Mechanisms of Immunodeficiency caused by HIV 
HIV infection ultimately results in impaired function of both the adaptive and innate 
immune systems. The most prominent defects are in cell-mediated immunity, and they 
can be attributed to several mechanisms, including direct cytopathic effects of the virus 
and indirect effects.  
Death of CD4+ T cells is a major cause of the decline in the number of these cells, 
especially in the acute phase of the infection. Several direct toxic effects of HIV on 
infected CD4+ cells have been described [11]: 
 The process of virus production, with expression of gp41 in the plasma membrane 
and budding of viral particles, may lead to increased plasma membrane permeability 
and the influx of lethal amounts of calcium, which induces apoptosis, or osmotic 
lysis of the cell caused by the influx of water. 
 Viral production can interfere with cellular protein synthesis and thereby lead to cell 
death. 
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 The plasma membrane of HIV-infected T cells fuse with uninfected CD4+ T cells by 
virtue of gp120-CD4 interaction, and multinucleated giant cells or syncytia are 
formed. The process of HIV-induced syncytia formation can be lethal to HIV-
infected T cells as well as to uninfected CD4+ T cells that fuse to the infected cells. 
However, this phenomenon has largely been observed in vitro, and syncytia are 
rarely seen in the tissues of patients with AIDS. 
Other mechanisms in addition to direct lysis of infected CD4+ T cells by virus have 
been proposed for the depletion and loss of function of these cells in HIV-infected 
individuals:  
 Chronic activation of the T cells may predispose the cells to apoptosis.  
 HIV-specific CTLs are present in many patients with AIDS, and these cells can kill 
infected CD4+ T cells. 
 Antibodies against HIV envelope proteins may bind to HIV-infected CD4+ T cells 
and target the cells for antibody-dependent cell-mediated cytotoxicity (ADCC). 
 Binding of gp120 to newly synthesized intracellular CD4 may interfere with normal 
protein processing in the endoplasmic reticulum and block cell surface expression of 
CD4, making the cells incapable of responding to antigenic stimulation.  
 Defective maturation of CD4+ T cells in the thymus.   
 
1.4 CLINICAL FEATURES OF HIV DISEASE 
As antiretroviral therapy is improving, many of the clinical manifestations are changing.  
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1.4.0 Transmission of HIV and Epidemiology of AIDS 
HIV is transmitted from one individual to another by three major routes: 
 Sexual contact is the most frequent mode of transmission, either between 
heterosexual couples (the most frequent mode of transmission in Africa and Asia) or 
between homosexual partners.   
 Mother-to-child transmission of HIV accounts for the majority of pediatric cases of 
AIDS. This type of transmission occurs most frequently in utero or during childbirth, 
although transmission through breast milk is also possible. 
 Inoculation of a recipient with infected blood or blood products is also a frequent 
mode of HIV transmission. Needles shared by intravenous drug abuser account for 
most cases of this form of transmission. With the advent of routine laboratory 
screening, transfusion of blood or blood products in a clinical setting accounts for a 
small portion of HIV infections.  
 Major groups at risk for the development of AIDS in the United States include 
homosexual or bisexual males, intravenous drug abusers, heterosexual partners of 
members of the other risk groups, and babies born of infected mothers. Health care 
workers have a small increased risk for infection.   
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1.4.1 Clinical Course of HIV Infection  
The acute phase of the illness, also called the acute HIV syndrome, is the period of 
viremia characterized by non-specific symptoms of infection. It develops in 50% to 70% 
of infected adults tipically 3 to 6 weeks after infection. There is a spike of plasma virus 
and a modest reduction in CD4+ T cell counts, but the number of blood CD4+ T cells 
often returns to normal. In many patients, however, the infection is occult and there are 
no symptoms [12].  
The chronic phase of clinical latency may last for many years. During this time, the 
virus is contained within lymphoid tissues, and the loss of CD4+ T cells is corrected by 
replenishment from progenitors. Patients are asymptomatic or suffer from minor 
infections [12]. Within 2 to 6 months after infection, the concentration of plasma virus 
stabilizes at a particular set-point, which differs among patients. The level of the viral 
set-point and the number of blood CD4+ T cells are clinically useful indicators of the 
progression of disease. As the disease progresses, patients become susceptible to other 
infections, and immune responses to these infections may stimulate HIV production and 
accelerate the destruction of lymphoid tissues. Cytokines, such as TNF, that are 
produced by the innate immune system in response to microbial infections are 
particularly effective in boosting HIV production. Thus, as the immune system attempts 
to eradicate other microbes, it brings about its own destruction by HIV. 
HIV disease progresses to the final and almost invariable lethal phase, called AIDS, 
when the blood CD4+ T cell count drops below 200 cells/mm3. HIV viremia may climb 
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dramatically as viral replication in other reservoirs accelerates unchecked. Patients with 
AIDS suffer from combinations of opportunistic infections, neoplasm, cachexia (HIV 
wasting syndrome), kidney failure, (HIV nephropathy), and CNS degeneration (AIDS 
encephalopathy) [12]. Because CD4+ helper T cells are essential for both cell-mediated 
and humoral immune response to various microbes, the loss of these lymphocytes is the 
main reason that patients with AIDS become susceptible to many different type of 
infections. Furthermore, many of the tumors that arise in patients with AIDS have a viral 
etiology, and their prevalence in the setting of AIDS reflects an inability of the HIV 
infected patient to mount an effective immune response against oncogenic viruses. Most 
of the opportunistic infections and neoplasms associated with HIV infection occur after 
the blood CD4+ T cell count drops below 200 cells/mm3. Cachexia is often seen in 
patients with chronic inflammatory diseases and may result from effects of 
inflammatory cytokines (such as TNF) on appetite and metabolism. The CNS disease in 
AIDS may be due to neuronal damage by the virus or by shed viral proteins such as 
gp120 and Tat as well as to the effects of cytokines elaborated by infected microglial 
cells. Many of these devastating consequences of HIV infection, including opportunistic 
infections and tumors, have been significantly reduced by highly active anti-retroviral 
therapy (HAART).  
Although this summary of the clinical course is true for the most severe cases, the rate of 
progression of the disease is highly variable, and some individuals are long-term non 
progressors (LTNPs) [13]. The immunologic correlates of variable progression remain 
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unknown. Also, recent anti-retroviral therapy as changed the course, and greatly reduced 
the incidence, of severe opportunistic infections (such as Pneumocystis) and tumors 
(such as Kaposi’s sarcoma). 
 
1.5 LABORATORY TESTING FOR INITIAL ASSESSMENT AND 
MONITORING OF ANTIRETROVIRAL THERAPY 
A number of laboratory tests are important for initial evaluation of HIV-infected patients 
upon entry into care, during follow-up if antiretroviral therapy (ART) has not been 
initiated, and prior to and after initiation or modification of therapy to assess virologic 
and immunologic efficacy of ART and to monitor for laboratory abnormalities that may 
be associated with antiretroviral (ARV) drugs.  
Two surrogate markers are used routinely to assess the immune function and level of 
HIV viremia: CD4 T-cell count (CD4 count) and plasma HIV RNA (viral load).  
 
1.5.0 CD4 T-cell count  
The CD4 T-count is the major laboratory indicator of immune function in patients with 
HIV infection. It is one of the key factors in deciding whether to initiate ARV therapy 
and prophylaxis for opportunistic infections, and currently it is the strongest predictor of 
disease progression and survival according to clinical trials and cohort studies [14, 15].  
In general, CD4 T-cell count should be monitored every 3–4 months to: 
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1. determine when to start ARV therapy in untreated patients (ARV therapy should be 
initiated in all patients with a CD4 count <350 cells/mm3 or with history of an AIDS-
defining illness), 
2. assess immunologic response to ART, and  
3. assess the need for initiation or discontinuation of prophylaxis for opportunistic 
infections. 
The absolute CD4 count is a calculated value based on the total white blood cell (WBC) 
count and the percentages of total and CD4+ T lymphocytes. This absolute number may 
fluctuate among individuals or may be influenced by factors that may affect the total 
WBC and lymphocyte percentages, such as use of bone marrow–suppressive 
medications or the presence of acute infections. In all these cases, CD4 percentage 
remains stable and may be a more appropriate parameter to assess the patient’s immune 
function. 
 
1.5.1 Plasma HIV RNA Testing  
Plasma HIV RNA (viral load or HIV viremia) should be measured in all patients at 
baseline and on a regular basis thereafter, especially in patients who are on treatment, 
because viral load is the most important indicator of response to antiretroviral therapy. 
Thus, viral load testing serves as a surrogate marker for treatment response [16] and can 
be useful in predicting clinical progression [17, 18]. Optimal viral suppression is 
generally defined as a viral load persistently below the level of detection (<20–
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75copies/mL, depending on the assay used). However, isolated “blips” (viral loads 
transiently detectable at low levels, typically <400 copies/mL) are not uncommon in 
successfully treated patients and are not thought to represent viral replication or to 
predict virologic failure [19]. For most individuals who are adherent to their 
antiretroviral regimens and who do not harbor resistance mutations to the prescribed 
drugs, viral suppression is generally achieved in 12–24 weeks, even though it may take 
longer in some patients.  
Plasma viral load should be measured before initiation of therapy and preferably within 
2–4 weeks, and not more than 8 weeks, after treatment initiation or after treatment 
modification. Repeat viral load measurement should be performed at 4–8-week intervals 
until the level falls below the assay’s limit of detection.  
Viral load should be repeated every 3–4 months or as clinically indicated. Some 
clinicians may extend the interval to every 6 months for adherent patients who have 
suppressed viral loads for more than 2–3 years and whose clinical and immunologic 
status is stable.  
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CHAPTER 2 
2.0 T-CELL IMMUNE RESPONSE AGAINST HIV INFECTION 
HIV infection may develop to AIDS at different rates in different individuals, with a 
spectrum varying from rapid progression to long-term non-progression. Therefore, 
owing to this variable evolution, it is essential to have tests which can accurately assess 
the stage of infection in an individual, as well as predict its course and its progression. 
Laboratory tests, used routinely in the management of HIV infected patients to assess 
the immune function and level of HIV viremia (CD4 T-cell count and plasma HIV 
RNA), are only indicators and not predictors of disease progression. 
In the last few years there has been great interest for the study of T-cell immune 
response against different viruses that are able to establish chronic infection (such as 
CMV, EBV, HSV, epatitis viruses, HIV) in order to identify immunologic markers of 
control/progression.  
These studies have shown great phenotypic and functional heterogeneity of the T-cell 
responses against these viruses in both animal and human models and some authors have 
suggested that this heterogeneity is regulated by the levels of viral/antigen load [20]. 
With regard phenotypic heterogeneity, a large number of surface markers have been 
used over time to define sub-populations of antigen-specific CD4+ and CD8+ T cells at 
different stages of differentiation. These markers include CD45RO, CD45RA, CD62L, 
CD28, CD27, CD7, CD57, CD127, and CCR7 [21, 22]. 
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Combined use of CD45RA (cell surface glycoprotein associated with the naïve T-cell 
phenotype) and CD27 (member of the tumor necrosis factor receptor family),  has been 
used in previous studies in order to separate four gamma delta T-cell subsets with 
distinct homing capacity and effector function, by flow cytometry [23, 24]: 
1) CD27+ CD45RA+, naïve cells;  
2) CD27+ CD45RA-, central memory cells;  
3) CD27- CD45RA-, effector memory cells;  
4) CD27- CD45RA+, terminally differentiated cells. 
In particular, naive and memory cells express lymph node homing receptors, abound in 
lymph nodes, and lack immediate effector functions. Conversely, memory and 
terminally differentiated cells, which express receptors for homing to inflamed tissues, 
are poorly represented in the lymph nodes while abounding at sites of inflammation, and 
display immediate effector functions [23].  
With regard functional heterogeneity, distinct populations of specific-CD4+ and -CD8+ 
T-cells have been identified on the basis of the ability to secrete interleukin-2 (IL-2) and 
interferon-γ (IFN-γ): three populations of CD4+ T-cells (single IL-2, dual IL-2/IFN-γ, 
and single IFN-γ), and two of CD8+ T-cells (dual IL-2/IFN-γ and single IFN-γ).  
There is a correlation between the patterns of cytokine secretion and the proliferation 
capacity. Antigen-specific CD4+ T-cell populations secreting only IL-2 (single IL-2) 
and both IL-2 and IFN-γ (dual IL-2/IFN-γ) and antigen-specific CD8+ T-cell population 
secreting both IL-2 and IFN-γ retain proliferation capacity, while CD4+ and CD8+ T-
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cells secreting only IFN-γ (single IFN-γ) have poor proliferation capacity [20, 25] (Fig. 
7A). However, proliferation of single IFN-γ secreting CD4+ and CD8+ T-cells can be 
promoted in the presence of an exogenous source of IL-2. 
Regarding to HIV-1 infection, recent studies have shown that virus-specific CD4+ T-cell 
response, during primary infection, was typically an effector response, consisting of 
single IFN-γ secreting CD4+ T-cells (monofunctional response) [26] and that, in the 
chronic phase of infection, it was strictly dependent upon a series of factors [27], 
including the lack of control of virus replication, the initiation of ARV therapy and the 
spontaneous control of virus replication as it may occur in a small (1%) percentage of 
subjects known as long-term non-progressors (LTNPs). Specifically, during chronic 
infection, in the absence of controlled virus replication, the HIV-1-specific CD4+ T-cell 
response,  remained predominantly an effector response [26, 28] whereas, in subjects 
successfully treated with ARV therapy or in LTNPs, who spontaneously control virus 
replication with viremia levels below 50 HIV-1 RNA copies per ml of plasma (the limit 
of detection of the standard PCR assay), it switched to a memory response consisting of 
single IL-2-, dual IL-2/IFN-γ, and single IFN-γ secreting CD4+ T-cells (polyfunctional 
response) [26, 28]. Similarly, the HIV-1-specific CD8+ T-cell response during primary 
infection was typically an effector response consisting of single IFN-γ secreting CD8+ 
T-cells (monofunctional response) and remained so during the chronic phase of 
infection, in the absence of controlled virus replication. In LTNP patients and only in 
30-40% of subjects successfully treated with antiviral therapy, the HIV-1-specific CD8+ 
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T-cell response was a memory response consisting of dual IL-2/IFN-γ and single IFN-γ 
secreting CD8+ T-cells (polyfunctional response) [26, 28, 29]. 
Therefore, the above results show that antiviral therapy-mediated suppression of virus 
replication is not associated with consistent detection of the IL-2 CD8+ T-cell response 
(dual-IL-2/IFN-γ cells), differently from HIV-1-specific CD4+ T-cell response that is 
constantly associated with the detection of single-IL-2 and dual-IL-2/IFN-γ secreting 
cells.  
Although there is not formal demonstration, it seems that polyfunctional T-cell 
responses, mediated by multiple-cytokine producing T-cells, are directly responsible for 
control of virus replication and prevention of virus-associated disease [30]. 
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2.1 AIMS OF THE STUDY 
The aims of my study were to carry-out a phenotypic and functional analysis of CD4+ 
and CD8+ T-cells in HIV-1 infected patients, enrolled in Policlinico Hospital, Palermo, 
treated and untreated with antiretroviral therapy in order to evaluate their immunological 
status and to analyse the serum cytokine profile in these patients in order to establish 
their immune-activation state.  
Our proposal was to correlate the immunological status with the viral activity (antigen 
load routinely used during the follow up of these patients) and the efficacy of ARV 
therapy in order to identify immunologic markers that help the clinician to predict 
progression of HIV disease and to define the most opportune time to initiate, modulate 
or interrupt therapeutic measures. 
 
2.2 MATERIALS AND METHODS 
2.2.0 Study population  
HIV-1 mono-infected adults, on regular follow-up at the AIDS Center, Infectious 
Disease Department of the University of Palermo, were enrolled in this study after 
written informed consent was obtained. 
All patients were admitted to the hospital every 3 months for physical examination and 
routine laboratory tests, including HIV viremia and CD4 T-cell count.  
From this cohort, we selected participants meeting criteria for one of five groups:  
I. “naïve” patients, defined as individuals never treated with ARV drugs;  
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II. virologic “controllers”, defined as ARV drug-untreated individuals with plasma 
HIV viremia below 10,000 copies RNA/ml; 
III. virologic “non controllers”, defined as ARV drug-untreated individuals with 
plasma HIV viremia above 10,000 copies/ml; 
IV. virologic “responders”, defined as ARV drug-treated individuals with 
undetectable plasma HIV viremia (<47 copies/ml);  
V. virologic “non responders”, defined as ARV drug-treated individuals with 
detectable plasma HIV viremia. 
In general, the “controllers” are clinically stable patients not receiving ARV therapy 
more than 3 years; the “non controllers” are immunocompromised patients, which 
experienced opportunistic infections (most frequently Mycobacterium avium complex 
infection, Cytomegalovirus retinitis, Pneumocystis jiroveci pneumonia), not receiving 
antiretroviral therapy because not compliant; the “responders” are patients on 
antiretroviral therapy, compliant, in excellent clinical conditions; the “non responders” 
are immunocompromised patients with high-level of phenotypic resistance to 
antiretroviral drugs, which experienced in the past opportunistic infections; finally, the 
“naïve” patients are all newly diagnosed asymptomatic cases of HIV-1 infection.  
Based on the foregoing it is clear that “virologic controllers” represent a unique natural 
human model in which to investigate correlates of immune protection.  
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Informations about demographic characteristics (age, gender, risk factors for HIV 
infection, ARV therapy) were all recorded in a database designed for this study and are 
summarized in Table 2.  
Table 2: Demographic characteristics of the study groups, n (%) 
 Naïve 
n = 5 
Controllers 
n = 5 
Non controllers 
n = 10 
Responders 
n = 20 
Non responders 
n = 10 
Male gender 3 (60) 3 (60) 7 (70) 12 (60) 6 (60) 
Risk group       
Blood Transfusion  - - - - - 
Homosexual men  3 (60) 1 (20) 3 (30) 4 (20) 2 (20) 
Intravenous drug use - 2 (40) 4 (40) 9 (45) 4 (40) 
Others  2 (40) 2 (40) 2 (20) 6 (30) 4 (40) 
Unknown - - 1 (10) 1 (5) - 
ARV therapy No No No Yes Yes 
 
Most patients were males and the most frequent risk factors for HIV infection were 
homosexual contact and intravenous drug use. Furthermore, in our cohort the 60% of  
patients were under antiretroviral therapy and the 40% of these had an undetectable 
HIV-RNA load (<47 copies/mL).  
Baseline mean value of CD4 T-cell counts and HIV-RNA loads for each group of 
patients is shown in Table 3.   
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Table 3: Baseline media of CD4 T-cell counts and HIV-RNA loads in the study groups 
 Naïve 
n = 5 
Controllers 
n = 5 
Non controllers 
n = 10 
Responders 
n = 20 
Non responders 
n = 10 
CD4 T-cell counts 540 978 105 1288 62 
HIV RNA load 23100 5250 20000 <47 2250 
CD4 T-cell count normal values 500-1500 cells/mm3 
 
2.2.1 Flow cytometry analysis 
Functional pattern. To study intracellular production of IFN-γ and IL-2, peripheral 
blood mononuclear cells (PBMC, 106/ml) were stimulated with HIV-1IIIB p55 Gag (5 
µg/ml, final concentration, NIH AIDS Research and Reference Reagent Program, 
Division of AIDS, NIAID, NIH), in the presence of monensin for 6 hrs at 37°C in 5% 
CO2. Subsequently, the cells were harvested, washed and stained with APC-conjugated 
anti-CD8 or anti-CD4 mAb (Becton Dickinson) in incubation buffer (PBS-1% FCS-
0.1% Na azide) for 30 min at 4°C. Later on, the cells were washed twice in PBS-1% 
FCS and fixed with PBS-4% paraformaldehyde overnight at 4°C. Fixation was followed 
by permeabilization with PBS-1% FCS-0.3% saponin–0.1% Na azide for 15 min at 4°C. 
Staining of intracellular cytokines was performed by incubation of fixed permeabilized 
cells with PE-labelled anti-IFN-γ (clone B27) and FITC-labelled IL-2 antibody (clone 
MQ1-17H12) or an isotype-matched control mAb. All mAbs were from BD 
Biosciences.  After two more washes in PBS containing 1% FCS, the cells were 
analyzed by FACSCalibur  flow cytometer (Becton Dickinson, Mountain View, CA) 
 24
and analyzed using FlowJo 8.3.3 software (Treestar). Initial gating was on the 
lymphocyte population by forward and side scatter, and analysis was performed on 
100,000 acquired events for each sample. For every sample 100,000 viable nucleated 
cells were acquired within each population. Data are reported after background 
correction and the percent  of cytokine secreted CD8 and CD4 T cells had to be at least 
> 2-fold higher than background for individual cytokine. 
2.2.2 Phenotypic analysis. To assess the phenotype of T cells, before and after HIV 
antigen stimulation as above reported, PBMC were harvested, washed and stained with  
anti-CD8 or anti-CD4 mAb and anti-CD45RA and  anti-CD27 mAbs, conjugated with 
different fluorochromes in incubation buffer (PBS-1% FCS-0.1% Na azide) for 30 min 
at 4°C. Cells were then washed twice in PBS with 1% FCS and analyzed by flow 
cytometry.  
 
2.2.3 Cytokine assay. Different cytokines (IL-1β, IL-2, IL-6, TNF-β, IL-4, IL-10, IL-
13, IP-10, IL-8, MIP-1 α, MIP-1β, MCP-1 and more) levels in sera from HIV patients 
was evaluated by xMAP multiplex technology on the Luminex platform (Luminex, 
Austin TX, USA), using Biorad reagents (Bio-Rad Life Sciences, CA, USA). Data were 
acquired and analyzed with the Bioplex Manager Software (Bio-Rad). Responses were 
scored positive if the value was 2 fold over the negative control.  
Preparation of the samples before analysis on the Luminex machinery was performed 
according to the ‘Sample protocol for washed capture sandwich immunoassay’ (January 
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2006) downloaded from http://www.luminexcorp.com, with a few modifications. 
Briefly, 50 μl of bead-solution (containing Assay buffer and 5000 beads) was added to 
the appropriate wells in a 96-wells Millipore filter plate. Fifty microlitre Assay buffer 
was added to each background well, 50 μl of a diluted standard serum pool, diluted 
twofold from 1:25 to 1:3200 to each standard well and 50 μl of diluted positive serum 
control, diluted 1:25 to each positive control well. Fifty microlitre sample, diluted to 
1:25 and 1:400, respectively was added to each sample well. Standards and positive 
controls were diluted in Assay buffer and samples were diluted in Assay buffer with 
10%Sample blocking buffer. After 30 min incubation at room temperature on a plate 
shaker and two washes, 50 μl of biotinylated detection antibody, diluted 1:1000 in Assay 
buffer with a final antibody concentration of 1.0 μg/ml was added to each well. After 
further 30 min incubation at room temperature on a plate shaker and two washes, 50 μl 
of diluted streptavidin-R-phycoerythrin, diluted 1:250 in Assay buffer was added to each 
well. After further 30 min incubation at room temperature on a plate shaker and two 
washes, the samples were analysed on the Luminex machinery. 
 
2.2.4 Statistical analysis 
Values of p were derived from two-tailed ANOVA tests. Values of p <0.05 were 
considered significant.  
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2.3 RESULTS 
A total of 50 subjects were studied, including 5 “naïve” patients, 5 “controllers”, 10 
“non controllers”, 20 “responders” and 10 “non responders”.  
All patients were followed for a period of 12 months, except for the naïve patients which 
were followed only 3 months because, on the basis of their clinical and immune-
virologic characteristics, it was necessary to start ARV therapy early. 
 
2.3.1 Functional analysis of CD4+ and CD8+ T-cells. For each group of patients, we 
measured the average percentage of CD4+  and CD8+ T-cells producing IFN-γ and/or 
IL-2, at different observation time (T0, T3, T6, T9 and T12), to evaluate the different 
state of T-cells and to find a correlation between immunological  and clinical status of 
the patients over time.  
We compared virologic “controllers” with virologic “non controllers” (Fig. 8). In the 
first group of patients we observed during the period of study that all T-cell subsets were 
represented, the average percentage of single IFN-γ producing T-cells did not change 
with regard to CD4+ T-cells whereas it was reduced with regard CD8+ T-cells and 
finally double cytokine producing T-cells (both CD4+ and CD8+) always were well 
represented, reaching values around 40%.   
On contrary, in the second group of patients we observed that single IFN-γ producing T-
cells (both CD4+ and CD8+) were much more represented than other T-cell populations, 
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reaching values around 80%, and double cytokine producing T-cells (both CD4+ and 
CD8+) were virtually absent. 
We also compared virologic “responders” with virologic “non responders” (Fig. 9). In 
the first group of patients we observed during the period of study that all T-cell 
populations were represented, the average percentage of single IFN-γ producing T-cells 
(both CD4+ and CD8+) reduced reaching lower levels that baseline after 6 months of 
therapy and finally double cytokine producing T-cells (both CD4+ and CD8+) were well 
represented reaching values 20-30%.   
In the second group of patients we observed that single IFN-γ producing T-cells were 
more represented than other T-cell populations (expecially with regard to CD8+), 
sometimes reaching values of 100%, and double cytokine producing T-cells (both CD4+ 
and CD8+) were virtually absent. 
In order to establish if the double cytokine producing cells are simply a consequence or 
a cause of the virologic control (as suggested by Pantaleo et al.), we evaluated the 
frequency of these cells both in patients with low viremia in the absence of therapy 
(“controllers”) and in those who were aviremic as a consequence of ARV therapy 
(“responders”). Through this comparison (Fig. 10), we found that the “controllers” had 
slightly higher total levels of double cytokine producing T-cells (mean total values of 
36.4 vs 35.9%). These data suggest but do not prove that these cells contribute to 
virologic control, at least in this group of patients. However, we can safely assume that 
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the absence of viremia does not in and of itself result in higher levels of double-cytokine 
producing cells. 
Finally, functional analysis of T-cell immune response in naïve patients was possible 
only for 3 months (T0 and T1) because these patients, on the basis of their clinical and 
immune-virologic characteristics, started early ARV therapy. However, despite the short 
period of study, we observed that double cytokine producing T-cells were very poorly 
represented compared to those producing a single cytokine (Fig. 11).  
 
2.3.2 Phenotype analysis of CD4+ and CD8+ T-cells. 
We also asked whether there were differences in the differentiation status of T-cells in 
“controller” and “responder” patients before and after HIV antigen stimulation. To 
perform this analysis, CD4+ and CD8+ T-cells were characterized by CD45RA and 
CD27, allowing discrimination of 4 phenotypically distinct subpopulations of T-cells:  
1) CD27+ CD45RA+, naïve cells (TNAIVE);  
2) CD27+ CD45RA-, central memory cells (TCM);  
3) CD27- CD45RA-, effector memory cells (TEM);  
4) CD27- CD45RA+, terminally differentiated cells (TEMRA). 
With regard to the phenotypic pattern of T-cells in “controllers”, we observed no 
significant difference after stimulation of both CD4+ and CD8+ T-cells with HIV-1IIIB 
p55. In particular, we found that in these patients among CD4+ T-cells there was a 
higher percentage of cells within the less differentiated phenotype (CD27+ CD45RA+/-) 
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and a lower percentage of cells within the more differentiated phenotype (CD27- 
CD45RA+/-) (Fig. 12A), whereas among CD8+ T-cells there was a higher proportion of 
effector memory cells (CD27- CD45-) (Fig. 12B). 
Instead, with regard to the phenotypic pattern of T-cells in “responders”, we observed 
any difference after stimulation of both CD4+ and CD8+ T-cells with HIV-p55. 
Compared to baseline CD4+, stimulated CD4+ and CD8+ T-cells shown a slight 
decrease of naïve T-cells and a slight increase of central memory and effector memory 
T-cells (Fig. 13). 
 
2.3.3 Cytokine production. By X-MAP technology, we analyzed 11 cytokines levels 
(IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-17, IFN-γ, IP-10, TNF-α) in the sera of 
“responder” and “non responder” patients, in order to evaluate if there was some 
correlation between their clinical and immune-virologic status and cytokine profile. 
Fig. 14 shows the average cytokines levels (in pg/ml) in “responder” (in blue) and “non 
responder” (in red) patients, during the 12 months of study.  
All patients showed a state of immune-activation, the degree of which correlated with 
viral load, being higher in the “non responders” group.  
In particular, we found that “non responder” patients had higher levels of inflammatory 
cytokines (IL-1, IL-2, IL-6, IFN-γ) and slight higher levels of immunoregulatory 
cytokines (IL-10) compared with “responders”.  
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IL-10 is a major regulator of innate and adaptive immunity because on the one hand it 
interferes with the production of inflammatory mediators by polymorphonuclear 
neutrophils, monocytes and macrophages and on the other hand it down-regulates 
antigen presentation and affects the function of CD4+ T-cells [31]. Although several 
reports suggest an increase of IL-10 levels during disease progression in HIV-infected 
patients, others have not confirmed this [32]. Nevertheless, several studies have shown 
that IL-10 production is induced in vivo and in vitro during HIV infection and that 
neutralization of endogenous IL-10 may improve defective antigen-specific T cell 
function in HIV-infected patients. On the other hand, IL-10 may inhibit T-cell apoptosis 
[33], a potential beneficial effect in these patients. Moreover, while IL-10 has been 
found to inhibit HIV replication in acutely infected macrophages at concentration that 
block endogenous cytokine secretion, lower IL-10 concentration appear to enhance HIV 
replication. Thus, the present data are conflicting and the contribution of IL-10 to the 
immunopathogenesis of HIV infection remains unclear, even though it is important to 
underline that we evaluated the serum profile of IL-10 and this analysis requires further 
study, e.g. the intracellular analysis of HIV-specific CD4+ and CD8+ T-cells.  
 
2.4 DISCUSSION 
In this study, we have analysed the phenotypical and functional patterns of circulating T-
cells and the serum cytokine profile in HIV-1 mono-infected patients with varying levels 
of viremia, on and off ARV therapy.  
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Although we have a modest study population, our results are consistent with recent 
observations from other authors which suggest an important role of polyfunctional 
immune responses in the viral replication control. Indeed, we have found that double 
cytokine producing T-cells are only represented in immunocompetent patients, both in 
the absence (“controllers”) and in the presence of ARV therapy (“responders”). 
Moreover, our data show that low levels of T-cell activation are evident in 
immunocompetent patients, both in the absence (“controllers”) and in the presence of 
ARV therapy (“responders”) and lower levels of inflammatory cytokines are evident in 
“responders” compared with “non responders”.  
This immunologic state suggests that in patients which control virus replication, the 
host’s immune system responds to HIV by expanding but not exhausting T-cells while 
maintaining a relatively quiescent immune system. One model to explain the relevance 
of double cytokine producing cells is that these, through IL-2 production, are associated 
with an improved proliferative capacity [25]. This model suggests that IL-2 production 
facilitates constant replenishment of T-cells providing ultimately an adequate immune-
competence.   
Polyfunctional immune response could represent either the cause of viral replication 
control or the consequence of low viremia. Recent studies suggest that the functional 
profile of T-cell immune response is largely determined by the duration and intensity of 
antigenic exposure, and is therefore mainly a consequence of viremia [20]. In our study, 
to establish if the double-cytokine producing cells are or not an effect of the virologic 
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control, we compared “controllers” with “responders”. Through this comparison (Fig. 
10), we observed that the former have slightly higher total levels of double cytokine 
producing T-cells. These data suggest but don’t prove that these cells contribute to 
virologic control because otherwise the absence viremia should result in higher levels of 
double cytokine producing T-cells. However, we can safely assume that the absence of 
viremia does not in and of itself result in higher levels of double cytokine producing 
cells. 
Viral replication is regulated by a complex network of both inflammatory and regulatory 
cytokines. Although there are conflicting reports regarding the role of certain cytokines, 
their contribution to the state of generalized immune activation is well acknowledged. 
Through serum cytokine analysis, we noted that all HIV-1 infected patients show a 
certain state of immune-activation, the degree of which correlates with viral load. In 
particular we found that “responder” have lower levels of inflammatory cytokines (IL-1, 
IL-2, IL-6, IFN-γ) and slight lower levels of immunoregulatory cytokines (such as IL-
10) compared with “non responders”, as consequence of virus replication control and 
therefore of less stimulation of immune system. This lends further credence to the 
hypothesis that IL-10 may play a role in the pathogenesis of HIV disease and it supports 
the notion that full immunological normalization may not be achieved during 
antiretroviral therapy.  
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2.5 CONCLUSION 
Our analysis on HIV-infected patients, according to the results shown by recent 
experimental studies, suggests that the presence of polyfunctional immune responses is a 
strong correlate of HIV control, both in the absence and in the presence of therapy. 
Therefore, the study of T-cell immune response together to analysis of serum cytokine 
profile, associated with two surrogate markers used routinely (CD4 T-cell count and 
HIV viremia) in the management of HIV-1 infected patients, could help the clinicians to 
predict progression of HIV disease and to define the most opportune time to initiate or 
interrupt therapeutic measures. In the first case, the absence of polyfunctional immune 
responses in naïve HIV-1 infected patients, on regular follow-up, may be an indicator 
for an earlier initiation of antiretroviral therapy and thus preserve immunologic function.  
In this regard, we report the case of M.P., an asymptomatic 25 year-old man who 
presented to our AIDS Center for HIV high risk-behaviours. After diagnosis of HIV-1 
infection, he initiated a regular follow-up at our Center. At baseline, he presented a CD4 
T-cell count of 550 cells/mm3 and an HIV viremia of 25,000 copies/ml. We enrolled 
this patients in our study and we carried-out a functional analysis of his T-cell immune 
response. Fig. 15 shows that at T0, double-cytokine producing T cells were absent 
whereas those producing a single cytokine (IFN-γ or IL-2) were predominant. Three 
months after, because of a rapid fall of CD4 T-cell count (<200 cells/mm3), M.P. 
initiated antiretroviral therapy.    
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In the second case, the presence of polyfunctional immune responses in HIV-1 infected 
patients on antiretroviral therapy, may be an important indicator to interruption or 
simplification of ARV therapy in order to avoid his long-term toxicity. In this regard, we 
report the case of A.G, a 43-year old HIV-1 infected woman in A3 CDC class (this class 
includes patients with asymptomatic infection and pre-treatment nadir CD4 T-cell count 
<200 cells/mm3), in excellent clinical conditions, receiving antiretroviral therapy from 
2005 with good immune-virologic results (CD4 T-cell count >1000 cells/mm3 and viral 
load <47 copies/ml). We enrolled this patients among “responder” patients and we 
carried-out a functional analysis of his T-cell immune response. Fig. 16 shows that at 
T0, double cytokine producing T-cells were much more represented that single cytokine 
producing T-cells. Five months later, our patient reported concerns about a loss of 
muscle mass and she was clinically diagnosed as having lipoatrophy of the upper and 
lower limbs.  
Finally, these results are very important for other two reasons. First, for the formulation 
of effective vaccines whose design requires knowledge of the types of immune 
responses that are most likely to be protective, and second for the development and 
assessment of new therapeutic approaches, particularly immunomodulating.  
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Fig. 1 Italian incidence of new HIV diagnoses (per 100,000 population), 2009 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 Percent distribution of new HIV diagnoses among Italians and non nationals,  
by year of diagnosis 
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Fig. 3 Median age of new HIV diagnoses, by year of diagnosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 Percent distribution of new HIV diagnoses, 
by exposure category and year of diagnosis 
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Fig. 5 New HIV diagnoses: CD4 count at diagnosis, 2009  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6 HIV structure 
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Fig. 7 Functionally distinct populations of Ag-specific CD4+ and CD8+ T cells 
identified by the assessment of IL-2 and IFN-γ secretion 
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Fig. 8 Functional analysis of T-cells. Comparison between Controllers and non Controllers 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9 Functional analysis of T-cells. Comparison between Responders and non Responders 
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Fig. 10 Functional analysis of T-cells. Comparison between Controllers and Responders 
  
 
 
 
 
 
 
 
 
 
 
Fig. 11 Functional analysis of T-cells in Naïve patients 
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Fig. 12 Phenotypic analysis of CD4+ and CD8+ T-cells in Controllers  
before and after HIV-p55 stimulation 
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Fig. 13 Phenotypic analysis of CD4+ and CD8+ T-cells in Responders  
before and after HIV-p55 stimulation 
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Fig. 14 Average cytokines levels in “responders” (in blue) and “non responders” (in red), 
during the period of study 
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Fig. 15 Functional analysis of CD4+ and CD8+ T-cells in a naive patient at T0 
 
 
 
 
 
Fig. 16 Functional analysis of CD4+ and CD8+ T-cells in a responder patient at T0 
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